Research programme: long-acting conjugate therapeutics - Hanmi Pharmaceutical

Drug Profile

Research programme: long-acting conjugate therapeutics - Hanmi Pharmaceutical

Alternative Names: HM 11760A; HM 1216OB; HM 12260b; LAPS-FSH; LAPS-IFNβ

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Blood coagulation factors; Erythropoietins; Follicle stimulating hormones; Glucagon-like peptides; Granulocyte colony-stimulating factors; Growth hormones; Interferons; Peptides
  • Mechanism of Action Blood coagulation factor replacements; Corticotropin-releasing-hormone-Inhibitors; Erythropoiesis stimulants; Factor X stimulants; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Granulocyte colony stimulating factor stimulants; Growth hormone-releasing hormone inhibitors; Intercellular signalling peptide and protein stimulants; Interferon alpha stimulants; Interferon beta stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acromegaly; Anaemia; Cancer; Growth disorders; Haemophilia; Hepatitis C; Infertility; Multiple sclerosis; Neutropenia; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in South Korea (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Growth-disorders in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top